[1]张华光.倍他乐克联合胺碘酮治疗顽固性室性早搏的疗效分析[J].医学信息,2018,31(05):128-130.[doi:10.3969/j.issn.1006-1959.2018.05.045]
　ZHANG Hua-guang.Efficacy of Betaloc Combined with Amiodarone in the Treatment of Intractable Ventricular Premature Beats[J].Journal of Medical Information,2018,31(05):128-130.[doi:10.3969/j.issn.1006-1959.2018.05.045]
点击复制

倍他乐克联合胺碘酮治疗顽固性室性早搏的疗效分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年05期
页码:
128-130
栏目:
药物与临床
出版日期:
2018-03-01

文章信息/Info

Title:
Efficacy of Betaloc Combined with Amiodarone in the Treatment of Intractable Ventricular Premature Beats
文章编号:
1006-1959（2018）05-0128-03
作者:
张华光
博白县人民医院心内科，广西 博白 537600
Author(s):
ZHANG Hua-guang
Department of Cardiology,Bobai People's Hospital,Bobai 537600,Guangxi,China
关键词:
倍他乐克; 胺腆酮; 室性早搏
Keywords:
Key words：Betaloc; Amine; Ventricular premature beat
分类号:
R541.7
DOI:
10.3969/j.issn.1006-1959.2018.05.045
文献标志码:
A
摘要:
目的 探讨倍他乐克联合胺碘酮治疗顽固性室性早搏的临床疗效及安全性。方法 选择我院2016年1月~2017年1月收治的顽固性室性早搏患者108例。按随机数字表法分为观察组和对照组,各54例，观察组采用常规治疗加用倍他乐克及胺碘酮口服，对照组则采用常规治疗加用倍他乐克口服，观察两组患者的临床疗效及安全性。结果 观察组总有效率为96.30%高于对照组的79.63%，差异有统计学意义（P<0.05）,且观察组治疗后室性早搏、心率及左室射血分数得到改善，改善水平优于对照组（P<0.05）。观察组不良反应发生率9.26%与对照组7.41%，差异无统计学意义（P>0.05）。结论 倍他乐克联合胺碘酮治疗顽固性室性早搏疗效显著，安全性好，是治疗顽固性室性早搏的最佳选择。
Abstract:
Abstract：Objective To investigate the clinical efficacy and safety of betaloc combined with amiodarone in the treatment of intractable ventricular premature beats.Methods 108 patients with intractable ventricular premature beats from January 2016 to January 2017 were selected.According to the digital table method they were divided into observation group and control group,54 cases each,the observation group was treated with routine therapy and betaloc and amiodarone,while the control group was treated with routine therapy and betaloc orally.The clinical efficacy and safety of the two groups were observed.Results The total effective rate of the observation group was 96.30% higher than that of the control group 79.63%,the difference was statistically significant(P<0.05),and the ventricular premature beat,heart rate and left ventricular ejection fraction were improved after treatment in the observation group,the improvement level was better than that in the control group(P<0.05),the incidence of adverse reactions in the observation group was 9.26% and that in the control group was 7.41%,there was no significant difference between the two groups(P>0.05).Conclusion Betaloc combined with amiodarone in the treatment of intractable ventricular premature beats is the best choice for the treatment of intractable ventricular premature beats.

参考文献/References:

[1]王心悦.胺碘酮与倍他乐克联合方案治疗120例室性心律失常的临床疗效观察[J].中国现代药物应用,2016,10(2):140-141. [2]赖翩翩.倍他乐克与胺碘酮联用对室性心律失常疗效观察[J].深圳中西医结合杂志,2016,26(16):129-130. [3]吴农田,李水花，徐兰芹.胺碘酮与配他乐克治疗室性能早搏56例及对心率变异性的影响[J].陕西医学杂志，2012,41(9):1219-1221. [4]王永,吕高荣.稳心颗粒治疗慢性肺源性心脏病合并频发室性期前收缩的临床疗效观察[J].中国全科医学，2012,15(3):909-910. [5]王小川,谢晓慧,陆浩,等.抗心律失常药物致心律失常作用的文献分析[J].中国医院药学杂志,2013,33(21):1825-1826. [6]肖国辉.胺碘酮联合倍他乐克治疗顽固性室性早搏22例[J].实用中西医结合临床,2011,11(1):46-47. [7]王峰,吴国霞,李玉兰.胺碘酮联合倍他乐克治疗室性心律失常的疗效观察[J].内蒙古医学杂志,2010,42(1):88-89. [8]耿勃.胺碘酮与倍他乐克配伍治疗室性早搏86例及对心率变异性的影响[J].黑龙江医药科学，2014,37(5)：116-117. [9]胡绍胜.应用倍他乐克和胺碘酮对难治性频发室性期前收缩患者治疗的临床观察[J].当代医学,2012,18(30):63. [10]李明俊.胺碘酮联合倍他乐克急诊治疗室性心律失常疗效评价[J].华北煤炭医学院学报,2011,13(6):795-796. [11]黄志军,李桃,杨淼泉,等.乙胺碘呋酮和倍他乐克治疗室性早搏的疗效与安全性的Meta分析[J].南方医科大学学报,2010,30(11):2577-2580.

相似文献/References:

[1]李春生.倍他乐克联合胺碘酮治疗阵发性房颤的疗效及对尿酸、SIRT1水平的影响[J].医学信息,2022,35(18):87.[doi:10.3969/j.issn.1006-1959.2022.18.022]
　LI Chun-sheng.Efficacy of Betaloc Combined with Amiodarone in the Treatment of Paroxysmal Atrial Fibrillation and its Effect on Uric Acid and SIRT1 Levels[J].Journal of Medical Information,2022,35(05):87.[doi:10.3969/j.issn.1006-1959.2022.18.022]
[2]蒲军亮,张 婷.沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性心力衰竭的疗效观察[J].医学信息,2020,33(14):159.[doi:10.3969/j.issn.1006-1959.2020.14.051]
　PU Jun-liang,ZHANG Ting.Observation of Sacubitril Valsartan Sodium Tablets Combined with Metoprolol Succinate Sustained-release Tablets in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2020,33(05):159.[doi:10.3969/j.issn.1006-1959.2020.14.051]
[3]杨启明,魏先森.诺欣妥、倍他乐克联合拜新同治疗老年高血压合并慢性心功能不全的临床研究[J].医学信息,2024,37(07):115.[doi:10.3969/j.issn.1006-1959.2024.07.022]
　YANG Qi-ming,WEI Xian-sen.A Clinical Study on the Treatment of Senile Hypertension Complicated with Chronic Cardiac Insufficiency by Ningroxinto, Betaloc Combined with Nifedipine[J].Journal of Medical Information,2024,37(05):115.[doi:10.3969/j.issn.1006-1959.2024.07.022]

更新日期/Last Update: 2018-03-01